Chemomab Therapeutics (CMMB) Shares Outstanding (2017 - 2025)

Chemomab Therapeutics' Shares Outstanding (Entity) history runs 3 years deep, the most recent figure standing at $88.7 million for Q2 2023.

• Quarterly Shares Outstanding (Entity) fell 2.85% year-over-year to $88.7 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $88.7 million (down 2.85% YoY) and the FY2022 annual result came in at $91.0 million, up 9.7% from the prior year.
• Shares Outstanding (Entity) was $88.7 million for Q2 2023 at Chemomab Therapeutics, roughly flat from $88.4 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $91.5 million in Q3 2022 and bottomed at $62.7 million in Q1 2021.
• A 3-year average of $86.5 million and a median of $89.9 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 45.51% — and 2023, when it retreated 3.11%.
• Chemomab Therapeutics' Shares Outstanding (Entity) stood at $83.0 million in 2021, then rose by 9.7% to $91.0 million in 2022, then fell by 2.6% to $88.7 million in 2023.
• Business Quant data shows CMMB's Shares Outstanding (Entity) at $88.7 million in Q2 2023, $88.4 million in Q1 2023, and $91.0 million in Q4 2022.